Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse
Kuniya Asai, … , Charles J. Homcy, Stephen F. Vatner
Kuniya Asai, … , Charles J. Homcy, Stephen F. Vatner
Published September 1, 1999
Citation Information: J Clin Invest. 1999;104(5):551-558. https://doi.org/10.1172/JCI7418.
View: Text | PDF
Article

β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse

  • Text
  • PDF
Abstract

Transgenic (TG) mice with cardiac Gsα overexpression exhibit enhanced inotropic and chronotropic responses to sympathetic stimulation, but develop cardiomyopathy with age. We tested the hypothesis that cardiomyopathy in TG mice with Gsα overexpression could be averted with chronic β-adrenergic receptor (β-AR) blockade. TG mice and age-matched wild-type littermates were treated with the β-AR blocker propranolol for 6–7 months, starting at a time when the cardiomyopathy was developing but was not yet severe enough to induce significant cardiac depression (9.5 months of age), and ending at a time when cardiac depression and cardiomyopathy would have been clearly manifest (16 months of age). Propranolol treatment, which can induce cardiac depression in the normal heart, actually prevented cardiac dilation and the depressed left ventricular function characteristic of older TG mice, and abolished premature mortality. Propranolol also prevented the increase in myocyte cross-sectional area and myocardial fibrosis. Myocyte apoptosis, already apparent in 9-month-old TG mice, was actually eliminated by chronic propranolol. This study indicates that chronic sympathetic stimulation over an extended period is deleterious and results in cardiomyopathy. Conversely, β-AR blockade is salutary in this situation and can prevent the development of cardiomyopathy.

Authors

Kuniya Asai, Gui-Ping Yang, Yong-Jian Geng, Gen Takagi, Sanford Bishop, Yoshihiro Ishikawa, Richard P. Shannon, Thomas E. Wagner, Dorothy E. Vatner, Charles J. Homcy, Stephen F. Vatner

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
LV function assessed by echocardiography. Shown are representative LV M-...
LV function assessed by echocardiography. Shown are representative LV M-mode echocardiographic recordings (a and b) and average data for LV function (c and d) in both untreated and propranolol-treated older TG mice at 15 months. Propranolol prevented LV dilation in older TG mice. LVEF and mean Vcfc are compared in untreated older (14- to 15-month-old) WT (light gray bars; n = 10), propranolol-treated WT (open bars; n = 14), untreated younger (9-month-old) TG (dark gray bars; n = 10), untreated older TG (black bars; n = 10), and propranolol-treated older TG mice (dotted bars; n = 9). LV function was significantly (P < 0.05) depressed in untreated older TG mice compared with age-matched untreated older WT mice, and depressed LV function was already observed in younger TG mice, whose ages are matched to the age of animals when the β-AR blockade therapy was begun. LV contractile function in propranolol-treated older TG mice was improved compared with that in both untreated younger and older TG mice. Error bars are ± SEM. *P < 0.05, †P < 0.05 vs. untreated WT mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts